CV Therapeutics, Inc. is a biopharmaceutical company headquartered in Palo Alto, CA. Focused on the development of novel small molecule therapeutics for the treatment of cardiovascular diseases, CV Therapeutics has emerged as a leader in cardiovascular medicine. In April 2009, CV Therapeutics was acquired by Gilead Sciences, Inc.
